.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Covington
Johnson and Johnson
US Department of Justice
UBS
Fuji
Julphar
Harvard Business School
Chubb
Fish and Richardson

Generated: September 24, 2017

DrugPatentWatch Database Preview

EVAMIST Drug Profile

« Back to Dashboard

What is the patent landscape for Evamist, and what generic Evamist alternatives are available?

Evamist is a drug marketed by Perrigo Pharma Intl and is included in one NDA. There are four patents protecting this drug.

This drug has fifty patent family members in seventeen countries.

The generic ingredient in EVAMIST is estradiol. There are seventy-five drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the estradiol profile page.

Summary for Tradename: EVAMIST

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list63
Clinical Trials: see list1
Patent Applications: see list9,668
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EVAMIST at DailyMed

Pharmacology for Tradename: EVAMIST

Ingredient-typeEstradiol Congeners
Drug ClassEstrogen
Mechanism of ActionEstrogen Receptor Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EVAMIST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007► Subscribe► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007► Subscribe► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: EVAMIST

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,916,486 Transdermal delivery of analgesics► Subscribe
6,998,138Topical delivery of anti-alopecia agents► Subscribe
6,964,777 Transdermal delivery of antianxiety agents► Subscribe
6,929,801 Transdermal delivery of antiparkinson agents► Subscribe
7,438,203Dermal penetration enhancers and drug delivery systems involving same► Subscribe
8,071,075Dermal penetration enhancers and drug delivery systems involving the same► Subscribe
6,916,487 Transdermal delivery of antiemetics► Subscribe
7,387,789Transdermal delivery of non-steroidal anti-inflammatory drugs► Subscribe
7,094,422Topical delivery of antifungal agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EVAMIST

Country Document Number Estimated Expiration
Luxembourg91971► Subscribe
Germany122012000019► Subscribe
Hong Kong1087355► Subscribe
World Intellectual Property Organization (WIPO)9729735► Subscribe
Japan2000504697► Subscribe
Japan2007326867► Subscribe
World Intellectual Property Organization (WIPO)0243611► Subscribe
Canada2244089► Subscribe
Australia2002220352► Subscribe
Denmark1674068► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EVAMIST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00523Netherlands► SubscribePRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
/2004Austria► SubscribePRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
C0002Belgium► SubscribePRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
972Luxembourg► Subscribe91972, EXPIRES: 20220219
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00521Netherlands► SubscribePRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Express Scripts
Harvard Business School
McKinsey
Daiichi Sankyo
Chubb
Baxter
US Department of Justice
Cipla
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot